{"id":"NCT03764293","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","briefTitle":"A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC","officialTitle":"A Randomized, Open-Label, International, Multi-Center, Phase 3 Clinical Study of PD-1 Antibody SHR-1210 Plus Apatinib Mesylate Versus Sorafenib as First-Line Therapy in Patients With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Previously Received Systemic Therapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-06-10","primaryCompletion":"2022-02-08","completion":"2023-06-14","firstPosted":"2018-12-05","resultsPosted":"2024-02-06","lastUpdate":"2024-02-06"},"enrollment":543,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Locally Advanced or Metastatic and Unresectable HCC"],"interventions":[{"type":"DRUG","name":"SHR-1210","otherNames":["Camrelizumab"]},{"type":"DRUG","name":"Apatinib","otherNames":["Rivoceranib"]},{"type":"DRUG","name":"Sorafenib","otherNames":[]}],"arms":[{"label":"SHR-1210","type":"EXPERIMENTAL"},{"label":"Control","type":"ACTIVE_COMPARATOR"}],"summary":"This is a randomized, open-label, international, multi-center, phase III trial to evaluate the efficacy and safety of SHR-1210 plus apatinib mesylate versus sorafenib as first-line therapy in patients with advanced HCC.","primaryOutcome":{"measure":"Overall Survival (OS)","timeFrame":"Up to approximately 3 years","effectByArm":[{"arm":"Camrelizumab+Rivoceranib Arm","deltaMin":22.1,"sd":null},{"arm":"Sorafenib Arm","deltaMin":15.2,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":10,"exclusionCount":22},"locations":{"siteCount":121,"countries":["United States","Belgium","China","Germany","Hong Kong","Italy","Poland","Russia","South Korea","Spain","Taiwan","Turkey (TÃ¼rkiye)","Ukraine"]},"refs":{"pmids":["37499670"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":114,"n":272},"commonTop":["Aspartate aminotransferase increased","Hypertension","Alanine aminotransferase increased","Palmar-plantar erythrodysaesthesia syndrome","Platelet count decreased"]}}